Response to Cabozantinib in patients with RET fusion-positive lung adenocarcinomas. Academic Article uri icon



  • The discovery of RET fusions in lung cancers has uncovered a new therapeutic target for patients whose tumors harbor these changes. In an unselected population of non-small cell lung carcinomas (NSCLCs), RET fusions are present in 1% to 2% of cases. This incidence increases substantially, however, in never-smokers with lung adenocarcinomas that lack other known driver oncogenes. Although preclinical data provide experimental support for the use of RET inhibitors in the treatment of RET fusion-positive tumors, clinical data on response are lacking. We report preliminary data for the first three patients treated with the RET inhibitor cabozantinib on a prospective phase II trial for patients with RET fusion-positive NSCLCs (NCT01639508). Confirmed partial responses were observed in 2 patients, including one harboring a novel TRIM33-RET fusion. A third patient with a KIF5B-RET fusion has had prolonged stable disease approaching 8 months (31 weeks). All three patients remain progression-free on treatment.

publication date

  • March 26, 2013



  • Adenocarcinoma
  • Anilides
  • Lung Neoplasms
  • Proto-Oncogene Proteins c-ret
  • Pyridines


PubMed Central ID

  • PMC4160032

Scopus Document Identifier

  • 84878858856

Digital Object Identifier (DOI)

  • 10.1158/2159-8290.CD-13-0035

PubMed ID

  • 23533264

Additional Document Info


  • 3


  • 6